Prognosis and Therapeutic Biomarkers for Glioblastoma Patients

Prognosis and Therapeutic Biomarkers for Glioblastoma Patients

The purpose of this study is to investigate if the potential biomarkers identified could be used for facilitating the diagnosis and prognosis of patients with glioblastoma (GBM).

The objective of this proposed study is to determine the expression levels of a panel of markers including CD133, CD44, ABCC3, TNFRSF1A, AKT1, IDH2, and MGMT in GBM tissues and the CSF, blood, and saliva from patients with GBM receiving different types of treatment (Optune only or Optune with TMZ) and the non-brain tumor patients (controls). Our aims are: 1) To compare the differences of CD44 between the control group and the combined cancer groups at baseline; and 2) To compare the levels of CD44 and other markers among the 3 different groups such as control vs. GBM patients and Optune vs. Optune + TMZ after 8 weeks of treatment. Exploratory analysis of all other markers will be performed.

Inclusion Criteria:

• 22 years old
• Control Group (only patients evaluated for neurological disorders whose evaluation require a lumbar puncture)
• Non-Control Group - Diagnosed with GBM (Glioblastoma)

Exclusion Criteria:

• Pregnancy
• Infectious Disease to include cold, flu, HIV, etc.
• Blood Disorder (example:low platelets, anemia, thrombosis)
• Vascular Malformations